Presented by Dr Leigh Goedeke, Yale School of Medicine this webinar details using spontaneous NHP models of NAFLD and metabolic syndrome to assess a controlled-release mitochondrial protonophore (CRMP). Explore proof-of-concept data from these clinically relevant models, supporting the development of novel liver-targeted mitochondrial uncouplers to treat human NASH and T2D.

Learn more about PDX-derived tumor organoids (PDXO) developed using HUB protocols, as robust in vitro models to improve the predictivity and speed of preclinical drug discovery. Review the main applications of 3D PDXO including large-scale drug screening, in vivo model selection, and in silico drug discovery.

Join Mike Batey to learn how to apply systems biology in early stage drug development for biomarker discovery and validation. Review 3 case studies exploring novel strategies to identify and utilize biomarkers using translational preclinical models, including using in vitro models to uncover genetic signatures of response and in vivo PDX to dissect drug MoA and guide clinical trial design.

Presented by Dr Sylvia Boj, Hubrecht Organoid Technology this webinar reviews the development and application of HUB Organoids. Explore the many advantages of HUB Organoids within 3D in vitro modeling, including direct clinical relevance and immuno-oncology applications.

Learn more about NHPs as a valuable early-stage preclinical platform for non-GLP exploratory toxicology studies. Explore the robust data these studies generate in a rapid, flexible, and cost-effective manner to assess immunotherapy safety and de-risk future clinical trials.

Learn how to optimize PDX mouse clinical trial design, use, and data output by moving beyond traditional analyses to a robust statistical framework. Explore case studies applying our published linear mixed models to enhance MCT study design, drug efficacy quantification, biomarker discovery and validation, as well as reinterpretation of clinical trial results.

Review the breakthrough discoveries leading to the development of HUB Organoids. Explore the key features of these 3D in vitro models including organ morphology recapitulation, stability, genomic superiority, and long-term culture, as well as their main utilities in research and development.

Explore the key features of commonly used preclinical IBD models, including model development and example treatment studies. Learn how to choose the most appropriate model for your drug development program, based on drug target and mechanism of action alongside model disease pathogenesis and clinical relevance.

Presented by Dr Fred Beasley this webinar explores how to select the most appropriate models for your preclinical obesity studies, including polygenic vs monogenic models and recommendations based on drug modes of action. We also review best practice in obesity study design to maximize data outcomes.